Association Between α-Tocopherol, γ-Tocopherol, Selenium, and Subsequent Prostate Cancer

Background: Selenium and α-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little attention has been paid to the possible role of γ-tocopherol, a major component of vitamin E in the U.S. diet and the second most common toco...

Full description

Saved in:
Bibliographic Details
Published inJNCI : Journal of the National Cancer Institute Vol. 92; no. 24; pp. 2018 - 2023
Main Authors Helzlsouer, Kathy J., Huang, Han-Yao, Alberg, Anthony J., Hoffman, Sandra, Burke, Alyce, Norkus, Edward P., Morris, J. Steven, Comstock, George W.
Format Journal Article
LanguageEnglish
Published Cary, NC Oxford University Press 20.12.2000
Oxford Publishing Limited (England)
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background: Selenium and α-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little attention has been paid to the possible role of γ-tocopherol, a major component of vitamin E in the U.S. diet and the second most common tocopherol in human serum. A nested case–control study was conducted to examine the associations of α-tocopherol, γ-tocopherol, and selenium with incident prostate cancer. Methods: In 1989, a total of 10 456 male residents of Washington County, MD, donated blood for a specimen bank. A total of 117 of 145 men who developed prostate cancer and 233 matched control subjects had toenail and plasma samples available for assays of selenium, α-tocopherol, and γ-tocopherol. The association between the micronutrient concentrations and the development of prostate cancer was assessed by conditional logistic regression analysis. All statistical tests were two-sided. Results: The risk of prostate cancer declined, but not linearly, with increasing concentrations of α-tocopherol (odds ratio highest versus lowest fifth = 0.65; 95% confidence interval = 0.32–1.32; Ptrend = .28). For γ-tocopherol, men in the highest fifth of the distribution had a fivefold reduction in the risk of developing prostate cancer than men in the lowest fifth (Ptrend = .002). The association between selenium and prostate cancer risk was in the protective direction with individuals in the top four fifths of the distribution having a reduced risk of prostate cancer compared with individuals in the bottom fifth (Ptrend = .27). Statistically significant protective associations for high levels of selenium and α-tocopherol were observed only when γ-tocopherol concentrations were high. Conclusions: The use of combined α- and γ- tocopherol supplements should be considered in upcoming prostate cancer prevention trials, given the observed interaction between α-tocopherol, γ-tocopherol, and selenium.
AbstractList Selenium and alpha-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little attention has been paid to the possible role of gamma-tocopherol, a major component of vitamin E in the U.S. diet and the second most common tocopherol in human serum. A nested case-control study was conducted to examine the associations of alpha-tocopherol, gamma-tocopherol, and selenium with incident prostate cancer. In 1989, a total of 10,456 male residents of Washington County, MD, donated blood for a specimen bank. A total of 117 of 145 men who developed prostate cancer and 233 matched control subjects had toenail and plasma samples available for assays of selenium, alpha-tocopherol, and gamma-tocopherol. The association between the micronutrient concentrations and the development of prostate cancer was assessed by conditional logistic regression analysis. All statistical tests were two-sided. The risk of prostate cancer declined, but not linearly, with increasing concentrations of alpha-tocopherol (odds ratio (highest versus lowest fifth) = 0.65; 95% confidence interval = 0.32--1.32; P(trend) =.28). For gamma-tocopherol, men in the highest fifth of the distribution had a fivefold reduction in the risk of developing prostate cancer than men in the lowest fifth (P:(trend) =.002). The association between selenium and prostate cancer risk was in the protective direction with individuals in the top four fifths of the distribution having a reduced risk of prostate cancer compared with individuals in the bottom fifth (P(trend) =.27). Statistically significant protective associations for high levels of selenium and alpha-tocopherol were observed only when gamma-tocopherol concentrations were high. The use of combined alpha- and gamma- tocopherol supplements should be considered in upcoming prostate cancer prevention trials, given the observed interaction between alpha-tocopherol, gamma-tocopherol, and selenium.
Selenium and alpha-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little attention has been paid to the possible role of gamma-tocopherol, a major component of vitamin E in the U.S. diet and the second most common tocopherol in human serum. A nested case-control study was conducted to examine the associations of alpha-tocopherol, gamma-tocopherol, and selenium with incident prostate cancer.BACKGROUNDSelenium and alpha-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little attention has been paid to the possible role of gamma-tocopherol, a major component of vitamin E in the U.S. diet and the second most common tocopherol in human serum. A nested case-control study was conducted to examine the associations of alpha-tocopherol, gamma-tocopherol, and selenium with incident prostate cancer.In 1989, a total of 10,456 male residents of Washington County, MD, donated blood for a specimen bank. A total of 117 of 145 men who developed prostate cancer and 233 matched control subjects had toenail and plasma samples available for assays of selenium, alpha-tocopherol, and gamma-tocopherol. The association between the micronutrient concentrations and the development of prostate cancer was assessed by conditional logistic regression analysis. All statistical tests were two-sided.METHODSIn 1989, a total of 10,456 male residents of Washington County, MD, donated blood for a specimen bank. A total of 117 of 145 men who developed prostate cancer and 233 matched control subjects had toenail and plasma samples available for assays of selenium, alpha-tocopherol, and gamma-tocopherol. The association between the micronutrient concentrations and the development of prostate cancer was assessed by conditional logistic regression analysis. All statistical tests were two-sided.The risk of prostate cancer declined, but not linearly, with increasing concentrations of alpha-tocopherol (odds ratio (highest versus lowest fifth) = 0.65; 95% confidence interval = 0.32--1.32; P(trend) =.28). For gamma-tocopherol, men in the highest fifth of the distribution had a fivefold reduction in the risk of developing prostate cancer than men in the lowest fifth (P:(trend) =.002). The association between selenium and prostate cancer risk was in the protective direction with individuals in the top four fifths of the distribution having a reduced risk of prostate cancer compared with individuals in the bottom fifth (P(trend) =.27). Statistically significant protective associations for high levels of selenium and alpha-tocopherol were observed only when gamma-tocopherol concentrations were high.RESULTSThe risk of prostate cancer declined, but not linearly, with increasing concentrations of alpha-tocopherol (odds ratio (highest versus lowest fifth) = 0.65; 95% confidence interval = 0.32--1.32; P(trend) =.28). For gamma-tocopherol, men in the highest fifth of the distribution had a fivefold reduction in the risk of developing prostate cancer than men in the lowest fifth (P:(trend) =.002). The association between selenium and prostate cancer risk was in the protective direction with individuals in the top four fifths of the distribution having a reduced risk of prostate cancer compared with individuals in the bottom fifth (P(trend) =.27). Statistically significant protective associations for high levels of selenium and alpha-tocopherol were observed only when gamma-tocopherol concentrations were high.The use of combined alpha- and gamma- tocopherol supplements should be considered in upcoming prostate cancer prevention trials, given the observed interaction between alpha-tocopherol, gamma-tocopherol, and selenium.CONCLUSIONSThe use of combined alpha- and gamma- tocopherol supplements should be considered in upcoming prostate cancer prevention trials, given the observed interaction between alpha-tocopherol, gamma-tocopherol, and selenium.
BACKGROUND: Selenium and alpha-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little attention has been paid to the possible role of gamma-tocopherol, a major component of vitamin E in the U.S. diet and the second most common tocopherol in human serum. A nested case-control study was conducted to examine the associations of alpha-tocopherol, gamma-tocopherol, and selenium with incident prostate cancer. METHODS: In 1989, a total of 10,456 male residents of Washington County, MD, donated blood for a specimen bank. A total of 117 of 145 men who developed prostate cancer and 233 matched control subjects had toenail and plasma samples available for assays of selenium, alpha-tocopherol, and gamma-tocopherol. The association between the micronutrient concentrations and the development of prostate cancer was assessed by conditional logistic regression analysis. All statistical tests were two-sided. RESULTS: The risk of prostate cancer declined, but not linearly, with increasing concentrations of alpha-tocopherol (odds ratio (highest versus lowest fifth) = 0.65; 95% confidence interval = 0.32--1.32; P(trend) =.28). For gamma-tocopherol, men in the highest fifth of the distribution had a fivefold reduction in the risk of developing prostate cancer than men in the lowest fifth (P:(trend) =.002). The association between selenium and prostate cancer risk was in the protective direction with individuals in the top four fifths of the distribution having a reduced risk of prostate cancer compared with individuals in the bottom fifth (P(trend) =.27). Statistically significant protective associations for high levels of selenium and alpha-tocopherol were observed only when gamma-tocopherol concentrations were high. CONCLUSIONS: The use of combined alpha- and gamma- tocopherol supplements should be considered in upcoming prostate cancer prevention trials, given the observed interaction between alpha-tocopherol, gamma-tocopherol, and selenium.
Background: Selenium and α-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little attention has been paid to the possible role of γ-tocopherol, a major component of vitamin E in the U.S. diet and the second most common tocopherol in human serum. A nested case–control study was conducted to examine the associations of α-tocopherol, γ-tocopherol, and selenium with incident prostate cancer. Methods: In 1989, a total of 10 456 male residents of Washington County, MD, donated blood for a specimen bank. A total of 117 of 145 men who developed prostate cancer and 233 matched control subjects had toenail and plasma samples available for assays of selenium, α-tocopherol, and γ-tocopherol. The association between the micronutrient concentrations and the development of prostate cancer was assessed by conditional logistic regression analysis. All statistical tests were two-sided. Results: The risk of prostate cancer declined, but not linearly, with increasing concentrations of α-tocopherol (odds ratio highest versus lowest fifth = 0.65; 95% confidence interval = 0.32–1.32; Ptrend = .28). For γ-tocopherol, men in the highest fifth of the distribution had a fivefold reduction in the risk of developing prostate cancer than men in the lowest fifth (Ptrend = .002). The association between selenium and prostate cancer risk was in the protective direction with individuals in the top four fifths of the distribution having a reduced risk of prostate cancer compared with individuals in the bottom fifth (Ptrend = .27). Statistically significant protective associations for high levels of selenium and α-tocopherol were observed only when γ-tocopherol concentrations were high. Conclusions: The use of combined α- and γ- tocopherol supplements should be considered in upcoming prostate cancer prevention trials, given the observed interaction between α-tocopherol, γ-tocopherol, and selenium.
Author Alberg, Anthony J.
Morris, J. Steven
Comstock, George W.
Burke, Alyce
Huang, Han-Yao
Hoffman, Sandra
Norkus, Edward P.
Helzlsouer, Kathy J.
Author_xml – sequence: 1
  givenname: Kathy J.
  surname: Helzlsouer
  fullname: Helzlsouer, Kathy J.
  organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia
– sequence: 2
  givenname: Han-Yao
  surname: Huang
  fullname: Huang, Han-Yao
  organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia
– sequence: 3
  givenname: Anthony J.
  surname: Alberg
  fullname: Alberg, Anthony J.
  organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia
– sequence: 4
  givenname: Sandra
  surname: Hoffman
  fullname: Hoffman, Sandra
  organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia
– sequence: 5
  givenname: Alyce
  surname: Burke
  fullname: Burke, Alyce
  organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia
– sequence: 6
  givenname: Edward P.
  surname: Norkus
  fullname: Norkus, Edward P.
  organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia
– sequence: 7
  givenname: J. Steven
  surname: Morris
  fullname: Morris, J. Steven
  organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia
– sequence: 8
  givenname: George W.
  surname: Comstock
  fullname: Comstock, George W.
  organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=908257$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/11121464$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1uEzEUhS3UiqaFNTs0AolVJ_HfjD3LEkFbtRVIKQhlYzmeO8JhYqe2R8BjVbxHnwmnCUV0gTeWpe9cn3vOIdpz3gFCLwgeE9ywydIZO2nomPIxxUQ-QSPCa1xSgqs9NMKYilJKwQ_QYYxLnE9D-VN0QAihGeQjND-J0Rurk_WueAvpO4Ar7m7La2_8-isE3x8Xd7_-ec6gB2eH1XGhXVvMhkWEmwFcKj4GH5NOUEy1MxCeof1O9xGe7-4j9On9u-vpWXn54fR8enJZGi5JKiXTnFHDmwVtq-yJsxZqYihuJdSilbhi2hjQnRBt08mubiouONRdq4XWmLIj9GY7dx18NhKTWtlooO-1Az9EJWjFuKyaDL56BC79EFz2pmhOjDJSb6CXO2hYrKBV62BXOvxUfyLLwOsdoKPRfRfysjY-cA2WtBKZmmwpk0OJAbq_g7DaVKc21amGKsrVprqsqB4pjE33vaSgbf8fXbnV2Zjgx8M3OnxTtWCiUmdf5upiPruaXdSf1ZT9BqiRrd0
CODEN JNCIEQ
CitedBy_id crossref_primary_10_1017_S0007114516000726
crossref_primary_10_1091_mbc_e03_07_0501
crossref_primary_10_1016_j_ctrv_2009_12_008
crossref_primary_10_1158_1940_6207_CAPR_10_0343
crossref_primary_10_1186_1475_2891_7_13
crossref_primary_10_1308_003588407X179125
crossref_primary_10_1093_jnci_dji009
crossref_primary_10_1007_s13749_013_0051_5
crossref_primary_10_1158_1055_9965_378_13_3
crossref_primary_10_1196_annals_1331_056
crossref_primary_10_1016_j_jaad_2006_04_014
crossref_primary_10_1016_j_ucl_2004_03_007
crossref_primary_10_2174_0115734137279106231227044328
crossref_primary_10_4137_LPI_S5788
crossref_primary_10_1080_07315724_2013_862490
crossref_primary_10_1194_jlr_M600291_JLR200
crossref_primary_10_1016_S0098_2997_03_00028_1
crossref_primary_10_1080_01635581_2012_630552
crossref_primary_10_1038_aja_2011_142
crossref_primary_10_1002_ijc_25033
crossref_primary_10_1073_pnas_102014399
crossref_primary_10_1079_BJN20051471
crossref_primary_10_1038_sj_pcan_4500569
crossref_primary_10_1111_jhn_12146
crossref_primary_10_1016_S0090_4295_01_01190_6
crossref_primary_10_1049_nbt2_12074
crossref_primary_10_1016_j_biomaterials_2011_05_032
crossref_primary_10_1080_10942912_2015_1114951
crossref_primary_10_1158_1055_9965_EPI_06_1071
crossref_primary_10_3945_ajcn_111_033373
crossref_primary_10_1097_01_ju_0000142058_99614_ff
crossref_primary_10_1016_j_ejca_2004_12_033
crossref_primary_10_1586_14737140_3_2_203
crossref_primary_10_1016_j_aninu_2020_11_010
crossref_primary_10_3389_fmars_2022_1092343
crossref_primary_10_1007_s12668_024_01431_y
crossref_primary_10_1200_JCO_2005_06_190
crossref_primary_10_1158_1055_9965_EPI_06_1084
crossref_primary_10_1080_1061186X_2024_2324935
crossref_primary_10_1002_pros_10115
crossref_primary_10_1093_ije_dyv156
crossref_primary_10_3390_molecules15031762
crossref_primary_10_1158_1055_9965_EPI_05_0585
crossref_primary_10_1016_S0090_4295_02_01641_2
crossref_primary_10_1016_j_bcp_2013_07_018
crossref_primary_10_1016_j_phymed_2017_06_008
crossref_primary_10_2135_cropsci2007_11_0658
crossref_primary_10_62313_ijpbp_2024_251
crossref_primary_10_1016_j_jaad_2014_01_910
crossref_primary_10_2135_cropsci2005_07_0227
crossref_primary_10_1016_S0094_0143_02_00181_7
crossref_primary_10_1039_C6RA11821F
crossref_primary_10_1158_1055_9965_EPI_13_0670
crossref_primary_10_1002_pros_21012
crossref_primary_10_4103_0022_3859_43549
crossref_primary_10_1158_1055_9965_EPI_05_0471
crossref_primary_10_1111_j_1464_410X_2004_04795_x
crossref_primary_10_1038_s41598_020_80433_8
crossref_primary_10_1002_mnfr_200800103
crossref_primary_10_1049_nbt2_12025
crossref_primary_10_1517_13543784_13_12_1541
crossref_primary_10_1111_j_1464_410X_2010_09344_x
crossref_primary_10_1017_S0954422407202938
crossref_primary_10_2203_dose_response_09_036_Chiang
crossref_primary_10_1016_j_coph_2009_06_002
crossref_primary_10_1093_carcin_bgp205
crossref_primary_10_1016_S0009_8981_03_00048_2
crossref_primary_10_1002_ijc_23689
crossref_primary_10_1038_nrurol_2010_102
crossref_primary_10_1007_s10552_005_0334_2
crossref_primary_10_1111_j_1527_3466_2005_tb00160_x
crossref_primary_10_1200_JCO_2008_18_8938
crossref_primary_10_3945_jn_111_153114
crossref_primary_10_1016_j_urolonc_2023_07_009
crossref_primary_10_1038_s41430_019_0460_7
crossref_primary_10_1007_s10620_006_9489_2
crossref_primary_10_1038_sj_bjc_6601701
crossref_primary_10_1093_jnci_djh125
crossref_primary_10_1016_j_jada_2004_12_021
crossref_primary_10_1007_s13197_011_0517_7
crossref_primary_10_1186_1471_2407_3_25
crossref_primary_10_1111_j_1365_2362_2010_02373_x
crossref_primary_10_4163_kjn_2010_43_3_304
crossref_primary_10_1152_japplphysiol_00421_2005
crossref_primary_10_3945_ajcn_2009_27535
crossref_primary_10_1016_j_spre_2007_10_002
crossref_primary_10_1007_s11934_005_0005_6
crossref_primary_10_1016_j_envres_2005_12_001
crossref_primary_10_1111_pbr_12362
crossref_primary_10_1016_j_bmc_2005_11_045
crossref_primary_10_2134_agronj2009_0140
crossref_primary_10_1207_S15327914nc391_9
crossref_primary_10_1093_jnci_djw153
crossref_primary_10_1016_j_jlumin_2017_02_056
crossref_primary_10_18632_oncotarget_15460
crossref_primary_10_1007_s10552_007_9072_y
crossref_primary_10_1017_S0007114507727447
crossref_primary_10_1080_10408398_2020_1711704
crossref_primary_10_1073_pnas_0408340102
crossref_primary_10_1093_jnci_djh137
crossref_primary_10_3802_jgo_2012_23_3_190
crossref_primary_10_1002_ijc_10866
crossref_primary_10_1002_pros_20915
crossref_primary_10_1016_j_urology_2004_04_012
crossref_primary_10_1093_jnci_djt456
crossref_primary_10_3945_ajcn_2008_26205
crossref_primary_10_1007_s11746_013_2330_0
crossref_primary_10_1080_02841860902946546
crossref_primary_10_1097_00005392_200112000_00006
crossref_primary_10_1021_jf0623844
crossref_primary_10_1079_PNS2005467
crossref_primary_10_1158_1535_7163_MCT_07_0172
crossref_primary_10_1080_10590501_2012_731957
crossref_primary_10_1002_mnfr_200800113
crossref_primary_10_1016_S1040_8428_03_00042_8
crossref_primary_10_1038_srep19213
crossref_primary_10_1093_jnci_djh147
crossref_primary_10_1207_S15327914NC421_14
crossref_primary_10_1158_1940_6207_CAPR_12_0045
crossref_primary_10_1016_j_jplph_2005_04_017
crossref_primary_10_1002_ijc_21058
crossref_primary_10_1158_1940_6207_CAPR_09_0152
crossref_primary_10_1007_s11356_015_4555_y
crossref_primary_10_1515_CCLM_2003_153
crossref_primary_10_1016_j_clinbiochem_2008_02_003
crossref_primary_10_3389_fsufs_2020_555426
crossref_primary_10_1158_1055_9965_EPI_16_0104
crossref_primary_10_1002_pros_22717
crossref_primary_10_1093_jnci_djj050
crossref_primary_10_1016_j_bbrc_2004_01_100
crossref_primary_10_1097_MD_0000000000005944
crossref_primary_10_1186_1471_2407_10_418
crossref_primary_10_1586_14737140_8_1_43
crossref_primary_10_1007_s00345_011_0810_0
crossref_primary_10_1080_13685530412331284722
crossref_primary_10_1016_j_ejca_2006_02_027
crossref_primary_10_1186_1472_6769_7_2
crossref_primary_10_1097_MOU_0b013e3280eb110f
crossref_primary_10_1097_00001622_200205000_00006
crossref_primary_10_1207_S15327914NC4601_01
crossref_primary_10_1200_JCO_2005_02_5460
crossref_primary_10_1016_j_nutres_2021_07_004
crossref_primary_10_1002_jsfa_3039
crossref_primary_10_1158_0008_5472_CAN_08_1827
crossref_primary_10_1002_ijc_24106
crossref_primary_10_1016_j_abb_2006_02_002
crossref_primary_10_1016_j_juro_2009_07_039
crossref_primary_10_1049_nbt2_12126
crossref_primary_10_3945_jn_111_141713
crossref_primary_10_3390_ijms24119240
crossref_primary_10_1158_1055_9965_EPI_17_1177
crossref_primary_10_1080_21691401_2017_1347941
crossref_primary_10_1007_s11745_002_0943_x
crossref_primary_10_1016_j_jmhg_2005_06_005
crossref_primary_10_1080_10715760100301411
crossref_primary_10_1289_EHP11391
crossref_primary_10_1080_10408398_2011_638424
crossref_primary_10_1016_j_msec_2016_05_004
crossref_primary_10_1016_S0278_6915_02_00331_9
crossref_primary_10_1016_j_currproblcancer_2004_05_002
crossref_primary_10_1207_S15327914NC4402_08
crossref_primary_10_1002_pros_23160
crossref_primary_10_1038_sj_pcan_4500825
crossref_primary_10_1089_ars_2016_6633
crossref_primary_10_1080_01635580802404162
crossref_primary_10_1016_S0891_5849_01_00618_9
crossref_primary_10_3390_curroncol31090405
crossref_primary_10_2903_j_efsa_2023_7704
crossref_primary_10_1080_10408390802304222
crossref_primary_10_1002_pros_20329
crossref_primary_10_1079_BJN20041251
crossref_primary_10_1158_1078_0432_CCR_05_0937
crossref_primary_10_3390_cancers15030979
crossref_primary_10_1002_14651858_CD005195_pub3
crossref_primary_10_1002_14651858_CD005195_pub4
crossref_primary_10_1007_s10552_006_0057_z
crossref_primary_10_1200_JCO_2005_03_1492
crossref_primary_10_1016_j_jpba_2016_03_021
crossref_primary_10_1016_j_nutres_2005_09_019
crossref_primary_10_1093_jnci_dji045
crossref_primary_10_1096_fj_02_0877com
crossref_primary_10_1093_ajcn_74_6_714
crossref_primary_10_1007_s00394_008_2005_z
crossref_primary_10_1097_00005392_200207000_00034
crossref_primary_10_1016_j_nutres_2011_03_005
crossref_primary_10_1158_1940_6207_CAPR_14_0058
crossref_primary_10_2174_1381612825666190123112647
crossref_primary_10_1016_j_urology_2003_09_019
crossref_primary_10_31665_JFB_2019_7192
crossref_primary_10_1093_jnci_dju005
crossref_primary_10_3148_66_2_2005_98
crossref_primary_10_1016_j_bbrc_2006_05_147
crossref_primary_10_1080_13685538_2018_1430129
crossref_primary_10_1002_pros_21162
crossref_primary_10_1093_jn_137_8_1974
crossref_primary_10_5483_BMBRep_2003_36_2_190
crossref_primary_10_1039_D2NJ04187A
crossref_primary_10_1200_JCO_2003_08_083
crossref_primary_10_1007_s10552_006_0064_0
crossref_primary_10_1046_j_1464_410X_2003_04167_x
crossref_primary_10_3390_md9112304
crossref_primary_10_1186_1475_2891_3_19
crossref_primary_10_1002_jsfa_2943
crossref_primary_10_1007_s12094_024_03692_1
crossref_primary_10_1186_1471_2407_6_13
crossref_primary_10_1080_01635581_2019_1653472
crossref_primary_10_34172_jhp_2020_15
crossref_primary_10_3389_fonc_2020_552907
crossref_primary_10_1007_s11918_009_0008_8
crossref_primary_10_1139_G10_021
crossref_primary_10_1016_j_mrfmmm_2005_04_021
crossref_primary_10_1016_S0022_5347_05_64850_1
crossref_primary_10_1016_j_freeradbiomed_2021_12_012
crossref_primary_10_1093_jnci_djn512
crossref_primary_10_1016_j_mrfmmm_2004_02_019
crossref_primary_10_1016_j_clindermatol_2010_03_026
crossref_primary_10_1007_s11912_004_0055_9
crossref_primary_10_1096_fj_02_0362fje
crossref_primary_10_1007_s10552_009_9304_4
crossref_primary_10_3109_07357907_2013_800095
crossref_primary_10_1177_1534735404270578
crossref_primary_10_1093_ajcn_85_1_209
crossref_primary_10_1158_1055_9965_EPI_10_0364
crossref_primary_10_1158_1535_7163_MCT_05_0389
crossref_primary_10_3961_jpmph_2009_42_1_67
crossref_primary_10_1080_01635580902825654
crossref_primary_10_1093_jn_133_10_3137
crossref_primary_10_7314_APJCP_2014_15_5_1897
crossref_primary_10_1371_journal_pone_0040204
crossref_primary_10_1158_1940_6207_CAPR_10_0259
crossref_primary_10_1038_sj_onc_1207716
crossref_primary_10_1023_A_1015844622285
crossref_primary_10_3389_fnut_2022_936189
crossref_primary_10_1155_2018_5703929
crossref_primary_10_1016_S0014_4800_03_00021_2
crossref_primary_10_1093_aje_kwn247
crossref_primary_10_1007_s11934_009_0029_4
crossref_primary_10_1016_S0022_5347_05_65500_0
crossref_primary_10_1016_j_canlet_2013_01_051
crossref_primary_10_1016_j_pop_2005_11_003
crossref_primary_10_1093_jnci_djt186
crossref_primary_10_3390_nu16234115
ContentType Journal Article
Copyright 2001 INIST-CNRS
Copyright Superintendent of Documents Dec 20, 2000
Copyright_xml – notice: 2001 INIST-CNRS
– notice: Copyright Superintendent of Documents Dec 20, 2000
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7TO
7U7
7U9
C1K
H94
K9.
NAPCQ
7X8
DOI 10.1093/jnci/92.24.2018
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Oncogenes and Growth Factors Abstracts
Toxicology Abstracts
Virology and AIDS Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Nursing & Allied Health Premium
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
Toxicology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Nursing & Allied Health Premium

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1460-2105
EndPage 2023
ExternalDocumentID 66045947
11121464
908257
10_1093_jnci_92_24_2018
ark_67375_HXZ_KZSMSK6V_C
Genre Research Support, U.S. Gov't, Non-P.H.S
Research Support, U.S. Gov't, P.H.S
Journal Article
GeographicLocations United States
North America
America
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: CA94028
GroupedDBID ---
-E4
-~X
.2P
.55
.GJ
.I3
.XZ
.ZR
08P
0R~
186
1TH
29L
2QL
2WC
354
3O-
4.4
482
48X
53G
5GY
5RE
5VS
5WD
70D
96U
AABZA
AACZT
AAGKA
AAHTB
AAJKP
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAWTL
ABCQX
ABDFA
ABEFU
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABNGD
ABNHQ
ABNKS
ABOCM
ABPEJ
ABPMR
ABPPZ
ABPTD
ABQLI
ABQNK
ABVGC
ABXVV
ABZBJ
ACBMB
ACGFO
ACGFS
ACGOD
ACKOT
ACNCT
ACPRK
ACUFI
ACUKT
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADXHL
ADYVW
AEGPL
AEJOX
AEKSI
AEMDU
AEMQT
AENZO
AEPUE
AETBJ
AETEA
AEWNT
AFAZI
AFCHL
AFFNX
AFFZL
AFIYH
AFOFC
AFRAH
AFXAL
AFYAG
AGINJ
AGKEF
AGNAY
AGORE
AGQPQ
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AI.
AIAGR
AIJHB
AJBYB
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
ASPBG
ATGXG
AVWKF
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BKOMP
BSCLL
BTRTY
BVRKM
C45
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
EE~
EJD
EMOBN
ENERS
F5P
F8P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GOZPB
GRPMH
GX1
H5~
HAR
HVGLF
HW0
HZ~
IH2
IOX
J21
J5H
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
LXL
LXN
LXY
M-Z
MHKGH
ML0
MVM
N9A
NGC
NOMLY
NOYVH
NTWIH
NVLIB
O0~
OAUYM
OAWHX
OBH
OCB
OCZFY
ODMLO
ODZKP
OGEVE
OHH
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PB-
PEELM
PQQKQ
Q.-
Q1.
Q5Y
R44
RD5
RNI
RNS
ROL
ROX
ROZ
RUSNO
RW1
RXO
RZF
RZO
TCURE
TEORI
TJX
TMA
TR2
TWZ
UDS
UPT
VH1
VVN
W8F
WH7
WOQ
X7H
X7M
Y6R
YAYTL
YHZ
YKOAZ
YQT
YR5
YXANX
ZKX
ZRR
ZY1
~91
~H1
~X8
AAYXX
CITATION
-DD
8WZ
A6W
AAJQQ
AAKAS
AAPGJ
AAQQT
AAWDT
ABSMQ
ACFRR
ACPQN
ACUTJ
ACVCV
ACZBC
ADMTO
ADZCM
AEHUL
AEKPW
AFFQV
AFSHK
AGKRT
AGMDO
AHGBF
AJDVS
APJGH
AQDSO
AQKUS
ATTQO
AVNTJ
BZKNY
EIHJH
FA8
H13
IQODW
MBLQV
NU-
OBFPC
O~Y
QBD
XJT
ABQTQ
ADJQC
ADRIX
ADZXQ
CGR
CUY
CVF
ECM
EIF
NPM
RHF
VXZ
YOT
7TO
7U7
7U9
C1K
H94
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c481t-83a432c49b2d546443de61c20d8e67d8053acceaf77d9f8f695474e6fda7aa023
ISSN 0027-8874
1460-2105
IngestDate Fri Jul 11 00:37:34 EDT 2025
Mon Jun 30 11:02:23 EDT 2025
Wed Feb 19 02:34:38 EST 2025
Mon Jul 21 09:17:59 EDT 2025
Tue Jul 01 00:44:56 EDT 2025
Thu Apr 24 23:13:17 EDT 2025
Tue Aug 05 16:49:04 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 24
Keywords Human
Urinary system disease
Prostate disease
α-Tocopherol
Case control study
Malignant tumor
E-Vitamins
Epidemiology
Micronutrient
Prevention
Risk factor
Male genital diseases
Prostate
Public health
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c481t-83a432c49b2d546443de61c20d8e67d8053acceaf77d9f8f695474e6fda7aa023
Notes Correspondence to: Kathy J. Helzlsouer, M.D., M.H.S., Department of Epidemiology, The Johns Hopkins University School of Hygiene and Public Health, 615 N. Wolfe St., Baltimore, MD 21205 (e-mail: Khelzlso@jhsph.edu).
local:0922018
istex:CE0436C607AB60A88A69E55270C6A11222C52BE3
ark:/67375/HXZ-KZSMSK6V-C
PII:1460-2105
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 11121464
PQID 221023169
PQPubID 41605
PageCount 6
ParticipantIDs proquest_miscellaneous_72534859
proquest_journals_221023169
pubmed_primary_11121464
pascalfrancis_primary_908257
crossref_primary_10_1093_jnci_92_24_2018
crossref_citationtrail_10_1093_jnci_92_24_2018
istex_primary_ark_67375_HXZ_KZSMSK6V_C
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2000-12-20
PublicationDateYYYYMMDD 2000-12-20
PublicationDate_xml – month: 12
  year: 2000
  text: 2000-12-20
  day: 20
PublicationDecade 2000
PublicationPlace Cary, NC
PublicationPlace_xml – name: Cary, NC
– name: United States
– name: Oxford
PublicationTitle JNCI : Journal of the National Cancer Institute
PublicationTitleAlternate JNCI J Natl Cancer Inst
PublicationYear 2000
Publisher Oxford University Press
Oxford Publishing Limited (England)
Publisher_xml – name: Oxford University Press
– name: Oxford Publishing Limited (England)
References 11121450 - J Natl Cancer Inst. 2000 Dec 20;92(24):1966-7
References_xml – reference: 11121450 - J Natl Cancer Inst. 2000 Dec 20;92(24):1966-7
SSID ssj0000924
Score 2.1898022
Snippet Background: Selenium and α-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little...
Selenium and alpha-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little...
BACKGROUND: Selenium and alpha-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However,...
SourceID proquest
pubmed
pascalfrancis
crossref
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2018
SubjectTerms Aged
Antioxidants
Biological and medical sciences
Case-Control Studies
Clinical trials
Humans
Incidence
Logistic Models
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Odds Ratio
Pathology
Prostate cancer
Prostatic Neoplasms - blood
Prostatic Neoplasms - etiology
Prostatic Neoplasms - prevention & control
Risk
Risk Factors
Selenium - administration & dosage
Selenium - blood
Tumors of the urinary system
Urinary tract. Prostate gland
Vitamin E
Vitamin E - administration & dosage
Vitamin E - blood
Title Association Between α-Tocopherol, γ-Tocopherol, Selenium, and Subsequent Prostate Cancer
URI https://api.istex.fr/ark:/67375/HXZ-KZSMSK6V-C/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/11121464
https://www.proquest.com/docview/221023169
https://www.proquest.com/docview/72534859
Volume 92
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgkxAvE_eFDcgDQkg0XeM4Fz9WZVNH1_KwFlV7MY7jIEaXojWV0H49x5dcWpi4vESRa6eJv-Pj4-PP5yD0OsMpBzsh84Iw4h6h2PfSKE08AlNzmPs4ldqnO55Ewxn5MA9bG-36dEmZdsXNb8-V_A-qUAa4qlOy_4Bs_VAogHvAF66AMFz_CuNW39aEK3141iuXQgcMMPmzvvCrq-0ylWWp-GqyHGvnOWgQTasuFWdLnzNSjDBh2buV_ToZnGovQsuQ1TTJyqc40E0aDkLja13cLFbLteVwNLtRw7X1WA_f1VZ1f1Gxzvqtiss833DXVr4KzfvAvbb-xTAnJiYvT6V_KW7JGSZtbdozuvkXNW9CYF0WQkFEcRcr75jV4xshtScf2cns7IxNj-fTu2gXw1pCpbl4fzpqpmuKbahu82pV_CcaHKk_OGoev2G67KpR-ENRafkKRlNu0qDcvk7R9sr0Adqz-Lh9IzUP0R1ZPEL3xpZK8Rh9bgmPa4XH3RaejrstOh23EpyOC2LjNmLjVmLjGrF5gmYnx9PB0LPpNjxBEr_0koCTAAtCU5yFBOzkIJORL3AvS2QUZwmoay6E5HkcZzRP8oiGJCYyyjMecw6231O0UywLuY9cTGFiCKnwc6hBqKRpniWwchBxILGIpYO6VU8yYWPRq5QoC2Y4EQFTXc8oZpgw1fUOels3-G7CsNxe9Y2Gpq7Hr78p9mIcsuH8go0uzsfno-gTGzjocAO7ugFVbpPYQQcVlMyO-RXDykMS-BF10Kv6V1DIapeNF3K5XrEYh4H6eAc9M_g3LwxrGzBMyPM_tj1A95vhc4h2yuu1fAHGb5m-1ML7EyrAsGE
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+alpha-tocopherol%2C+gamma-tocopherol%2C+selenium%2C+and+subsequent+prostate+cancer&rft.jtitle=JNCI+%3A+Journal+of+the+National+Cancer+Institute&rft.au=Helzlsouer%2C+K+J&rft.au=Huang%2C+H+Y&rft.au=Alberg%2C+A+J&rft.au=Hoffman%2C+S&rft.date=2000-12-20&rft.issn=0027-8874&rft.volume=92&rft.issue=24&rft.spage=2018&rft_id=info:doi/10.1093%2Fjnci%2F92.24.2018&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0027-8874&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0027-8874&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0027-8874&client=summon